MGMT and glioblastoma: More recently, a phase III multicentric trial has shown that temozolomide, in addition to short-course radiation therapy, doubled median survival in elderly (>65 years) glioblastoma patients with methylated MGMT gene with respect to patients with unmethylated MGMT gene (13.5 months versus 7.7 months, the hazard ratio for death, 0.53; 95% CI, from 0.38 to 0.73; p < 0.001) without increasing toxic effects.